Cytokinetics reports positive MAPLE-HCM results, sets investor event for Sept. 2.

• Cytokinetics to present aficamten data at European Society of Cardiology Congress 2025. • MAPLE-HCM primary results to be shared in Hot Line presentation. • Late Breaking Clinical Science session to present incidence and impact of atrial fibrillation. • Aficamten clinical trials in obstructive hypertrophic cardiomyopathy to be highlighted. • Investor event and webcast scheduled for September 2, 2025.

Title: Cytokinetics to Present Aficamten Data at European Society of Cardiology Congress 2025

Cytokinetics, Incorporated (Nasdaq: CYTK), a specialty cardiovascular biopharmaceutical company, has announced five presentations related to aficamten at the European Society of Cardiology Congress 2025. The presentations will highlight the drug's clinical performance in treating obstructive hypertrophic cardiomyopathy (HCM). The most significant presentation will be the primary results from MAPLE-HCM, a head-to-head comparison of aficamten versus metoprolol, which will be featured in the prestigious Hot Line session. This direct comparison against a standard-of-care beta-blocker is critically important for establishing aficamten's clinical value proposition [1].

The presentations will also cover the incidence and impact of atrial fibrillation across three clinical trials of aficamten (REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM). Atrial fibrillation affects approximately 20-25% of HCM patients and significantly increases stroke risk and mortality. Understanding aficamten's effect on this common complication could differentiate it from other treatments [1].

Additional presentations will cover long-term safety and efficacy data from FOREST-HCM, effects on cardiac structure and function from MAPLE-HCM, and an integrated safety analysis across trials. Collectively, these presentations will provide a comprehensive assessment of aficamten's clinical profile, including efficacy, safety, and potential advantages over current standard therapy [1].

The prominence of these presentations at a major cardiology congress, particularly the inclusion in Hot Line and Late-Breaking sessions, suggests Cytokinetics has confidence in positive results. For patients with obstructive HCM, who currently have limited treatment options that directly address the underlying pathophysiology, aficamten represents a potential paradigm shift in management by directly targeting cardiac contractility through myosin inhibition rather than merely controlling symptoms [1].

Cytokinetics will host an investor webcast on September 2, 2025, at 8:30 AM Eastern Time to discuss the primary results from MAPLE-HCM and other data presented at the European Society of Cardiology Congress 2025. Interested parties can register online at [https://cytokinetics-esc-2025.open-exchange.net/](https://cytokinetics-esc-2025.open-exchange.net/) [2]. The live webcast will be available on the Investors & Media section of the Cytokinetics website at [https://www.cytokinetics.com/](https://www.cytokinetics.com/). A replay of the webcast will be archived on the Cytokinetics website for six months [2].

References
[1] https://finance.yahoo.com/news/cytokinetics-announces-five-presentations-related-113000524.html
[2] https://www.stocktitan.net/news/CYTK/cytokinetics-announces-five-presentations-related-to-aficamten-at-h8iuo55p51wl.html